Los Angeles Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Los Angeles Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.08M	Sell	124,357 -12,242	-9%	-$292K	0.01%	413
2025 Q4	$2.86M	Sell	136,599 -25,800	-16%	-$575K	0.01%	381
2025 Q3	$3.2M	Sell	162,399 -21,976	-12%	-$452K	0.01%	401
2025 Q2	$4M	Sell	184,375 -3,941	-2%	-$93K	0.02%	337
2025 Q1	$4.57M	Sell	188,316 -15,708	-8%	-$354K	0.02%	304
2024 Q4	$4.26M	Buy	204,024 +3,742	+2%	+$80.4K	0.02%	342
2024 Q3	$3.98M	Buy	200,282 +123,020	+159%	+$2.28M	0.02%	340
2024 Q2	$1.2M	Sell	77,262 -3,755	-5%	-$58.5K	﹤0.01%	599
2024 Q1	$1.29M	Buy	81,017 +35,066	+76%	+$528K	﹤0.01%	609
2023 Q4	$772K	Sell	45,951 -41,330	-47%	-$565K	﹤0.01%	757
2023 Q3	$1.02M	Sell	87,281 -941	-1%	-$12.6K	﹤0.01%	638
2023 Q2	$1.19M	Sell	88,222 -21,951	-20%	-$316K	﹤0.01%	615
2023 Q1	$1.83M	Sell	110,173 -17,462	-14%	-$288K	0.01%	517
2022 Q4	$2.37M	Sell	127,635 -13,907	-10%	-$214K	0.01%	478
2022 Q3	$1.82M	Sell	141,542 -226,092	-61%	-$2.68M	0.01%	524
2022 Q2	$2.58M	Buy	367,634 +131,159	+55%	+$962K	0.01%	472
2022 Q1	$1.96M	Sell	236,475 -50,370	-18%	-$356K	0.01%	538
2021 Q4	$1.94M	Buy	286,845 +55,880	+24%	+$367K	0.01%	523
2021 Q3	$1.22M	Buy	230,965 +57,180	+33%	+$313K	0.01%	677
2021 Q2	$999K	Buy	+173,785	New	+$897K	﹤0.01%	859
2021 Q1	–	Sell	-362,065	Closed	-$1.21M	–	1591
2020 Q4	$1.21M	Sell	362,065 -26,320	-7%	-$88.4K	0.01%	852
2020 Q3	$1.15M	Sell	388,385 -86,485	-18%	-$338K	0.01%	769
2020 Q2	$2.19M	Buy	474,870 +159,865	+51%	+$718K	0.01%	594
2020 Q1	$1.21M	Buy	315,005 +208,445	+196%	+$856K	0.01%	664
2019 Q4	$400K	Buy	106,560 +3,350	+3%	+$15.7K	﹤0.01%	1064
2019 Q3	$548K	Buy	103,210 +8,250	+9%	+$44K	﹤0.01%	955
2019 Q2	$365K	Buy	94,960 +52,260	+122%	+$226K	﹤0.01%	1125
2019 Q1	$218K	Hold	42,700	–	–	﹤0.01%	1285
2018 Q4	$82K	Sell	42,700 -200	-0.5%	-$573	﹤0.01%	1244
2018 Q3	$162K	Buy	42,900 +25,940	+153%	+$81.3K	﹤0.01%	1353
2018 Q2	$53K	Buy	+16,960	New	+$51.5K	﹤0.01%	1424

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Los Angeles Capital Management's CPRX Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Catalyst Pharmaceutical (CPRX) stake by 9% in Q1 2026, selling an estimated $292K and leaving 124,357 shares worth $3.08M. The position accounts for 0.01% of the portfolio, ranked #413.

Los Angeles Capital Management first reported a position in CPRX in Q2 2018 and has held it in 31 quarters since. The position peaked at $4.57M in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Los Angeles Capital Management held 124,357 shares of Catalyst Pharmaceutical worth $3.08M as of Q1 2026.
Los Angeles Capital Management sold 12,242 Catalyst Pharmaceutical shares in Q1 2026, an estimated $292K.
Catalyst Pharmaceutical made up 0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #413 holding.
Los Angeles Capital Management first reported a position in Catalyst Pharmaceutical in Q2 2018 and has held it in 31 quarters since.
Los Angeles Capital Management's Catalyst Pharmaceutical position peaked at $4.57M in Q1 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.